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ABSTRACT
Background: Specific immunotherapy for bronchial asthma has been documented to be efficacious in several
studies ; however, it is not known whether this efficacy is sustained for several years after cessation of immu-
notherapy. The aim of this study is to determine the efficacy of house dust mite immunotherapy over a 15-year
period.
Methods: This study is an open, parallel, comparative trial in which 31 patients were administered immuno-
therapy for 5 years and then followed-up for a further 10 years. Their global symptom scores and FEV1 values
were compared with another group of 38 patients who refused immunotherapy.
Results: The use of immunotherapy resulted in a statistically significant improvement in both global symptom
scores and FEV1 in patients receiving immunotherapy when compared with those in the control group who did
not receive immunotherapy. This improvement was sustained for at least 10 years after cessation of immuno-
therapy.
Conclusions: The benefits of house dust mite immunotherapy are significant and sustained, a decade after
its discontinuation.
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INTRODUCTION
Specific immunotherapy (SIT) has been used in the
management of allergic diseases since 1911.1 Several
studies have clearly documented the clinical efficacy
of SIT in house dust mite allergy, yet this mode of
therapy remains controversial , 2 especially in bron-
chial asthma ( BA ) despite the fact that 3 meta-
analyses have proven the beneficial effects in this
condition.3-5
A very important question to be answered is
whether the effects of SIT are long lasting, particu-
larly after it has been discontinued. If the answer is
yes, it would make SIT an attractive, disease modify-
ing, treatment modality for allergic diseases such as
asthma andor rhinitis.
This study is a prospective , open, parallel , com-
parative trial of SIT versus a control group of patients
who did not receive SIT.
METHODS
INVESTIGATIONS
85 selected patients with BA (of more than 512 newly
detected BA cases who attended the clinic during the
year 1986) were subjected to a detailed history and
physical examination. Each patient underwent the fol-
lowing investigations：
( 1 ) Estimation of serum IgE levels ( radio-
immunoassay)
(2) Skin prick tests (SPT) with a battery of com-
mon Indian allergens (ALCIT India Pvt. Ltd., Delhi,
India)6
(3) Specific IgE levels (RAST) to the house dust
mite D. farinae.
(4) Spirometry
(5) Peak nasal inspiratory flow rates (PNFIR) using
a Youlten’s nasal flow meter (Clement Clark Interna-
tional, London, UK)．
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CRITERIA
The criteria for selecting patients for this study
were :
(1) Symptoms of perennial BA alone, with no evi-
dence of rhinitis or skin allergies. Patients with sea-
sonal BA were excluded from this study so as to
avoid intermittent variations in parameters studied.
Patients with rhinitis (which in India co-exists with
asthma in 55% of cases)6 were excluded, since vari-
ation in symptoms of rhinitis could have falsely al-
tered the patients’ perception of asthma symptom
scores.
(2) Elevated total serum IgE levels (normal value 0
to 50 IUml)
(3) Reduced FEV1 (obstructive airway disease on
spirometry).7
(4 ) Normal PNIFR (normal value 100 to 300
Lmin)
(5) Positive SPT results (2+ or more) to D. farinae.
(6) Positive RAST to D. farinae (>class III)．
Although an attempt was made to do so, social ob-
jections precluded any house dust mite measure-
ments from patients’ homes. Patients who had been
previously treated with SIT or those in whom there
were any known contraindications for administering
SIT were excluded from this study. Every patient was
found to have taken some form of therapy for BA
prior to this study, including oral and inhaled corti-
costeroids and beta2-agonists ; hence, a washout pe-
riod of 3 months preceded the beginning of the trial
during which only inhaled salbutamol was permitted．
A double blind, placebo controlled trial was con-
templated, but was not possible in view of the long-
term nature of this study．
RANDOMIZATION
A core group of 197 patients were randomly selected
using a random allocation table from the 512 new
asthmatics that attended the clinic in 1986. Each pa-
tient was offered SIT and inhaled corticosteroids
( ICS) . Beclomethasone dipropionate was the only
ICS available in India in the form of MDI when the
study was initiated. Patients who accepted SIT but re-
fused ICS were placed in Group 1 (SIT group) and
those who refused both SIT and ICS were placed in
Group 2 (control group). There were 46 men and 39
women among the 85 patients who were finally se-
lected in both groups：
Group 1 : The specific immunotherapy group (SIT
group) had 37 patients (22 men and 15 women), of
which 6 patients (4 men and 2 women) dropped out
from the study. Thus 31 patients (18 men and 13
women) completed the study with ages ranging from
8 years to 28 years (mean age 19.77 years)．
Group 2 : The control group consisted of patients
who refused SIT as well as ICS ; it initially consisted
of 48 patients (24 men and 24 women) of which 10 pa-
tients (4 men and 6 women) dropped out for a final
tally of 38 patients (20 men and 18 women) who com-
pleted the study. The age range in this group was 11
years to 35 years (mean age 22.61 years)．
None of the 85 patients finally selected were pre-
scribed or administered ICS during the entire study
period. Since this was a prospective, long-term study,
allocation to either the SIT or the placebo group
could not be randomized. No attempt was made to
stratify the patients during selection or allotment of
patients. Informed consent was obtained from every
patient (or their parents in case of minors) before in-
duction into the study．
STUDY PLAN
Avoidance Measures
Each patient was given instructions regarding appro-
priate avoidance measures, depending on their SPT
results. Avoidance measures for house dust included
removal of carpets , frequent vacuuming , changing
bedding to synthetic material such as foam and re-
moval of soft toys . All measures suggested were
strictly scrutinized and audited at each clinic visit, so
that they would, as far as possible, result in uniform
benefits.
Rescue Medication
Patients in both groups were trained in the use of a
salbutamol metered dose inhaler (MDI) through a
large volume spacer device (750 ml ). Each patient
was instructed to use salbutamol as a rescue medica-
tion only．
SIT Vaccines
Patients in the SIT group were given a course of sub-
cutaneous desensitizing vaccines , which contained
the dust mite D. farinae alone (Alcit India Pvt. Ltd.,
Delhi, India). D. farinae is a more common allergen
in India than D . pteronyssinus . 6 Vaccines were
started simultaneously in all 31 patients in the SIT
group on January 1, 1987. These were administered
in increasing strength, beginning with 1 : 25,000 wv
conc. to a maximum of 1 : 50 wv conc., in increas-
ing doses (0.1 ― 1.0 ml ) and decreasing frequency,
beginning with twice a week, then once a week and
later once in two weeks. The maximal dose of 1.0 ml.,
1 : 50 wv conc., was reached at the end of 30 weeks
followed by administration of a once in 2 weeks main-
tenance dose (1.0 ml, 1 : 50 wv conc.). Vaccines in
the SIT group were administered from January 1,
1987 to December 31, 1991, and then discontinued.
Subsequently both groups were asked to continue
with avoidance measures and rescue salbutamol until
the end of the study on December 31, 2001. During
the five-year vaccination period (1987 to 2001), vac-
cines in India were still quantified as wv. However,
as a part of a later study,8 it was determined that the
strength of the vaccines administered was approxi-
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Fig. 1　Percentage change and variation in FEV1 in the control (C) and specific immunotherapy (SIT) 
groups over a period of 15 years
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mately 40 bioequivalent allergy units (BAUml) to
start with9 a maximum of 8000 BAUml during the
maintenance phase, which would be designated as
“high dose．”All the instructions provided by the
manufacturer (Alcit India Pvt. Ltd.) were carefully fol-
lowed. Side effects of SIT (local and systemic) if any,
were observed and carefully recorded at each consul-
tation. Between January 1, 1987 and December 31,
2001, while the study was ongoing, symptom scores
and FEV1 of each patient were recorded once every 3
months on the first day of March, June, September
and December．
Symptom Scores
Symptom scores were assessed on a visual analogue
scale (VAS) from 0 to 10, where“0”indicated wors-
ening or no improvement and 10 indicated maximal
improvement. While assessing symptom scores, pa-
tients were instructed to make a global evaluation, in-
cluding frequency and severity of symptoms , pres-
ence of other complaints such as cough and phlegm
and improvement in quality of life．
Since symptom scores were evaluated for a lengthy
15 year period, the possibility of patients forgetting
their initial global symptom severity and intensity was
kept in mind . Consequently during the symptom
score evaluation period every attempt was made to
jog the patients memory, re-live symptom severity at
the beginning of the study, compare it with the status
on evaluation day and then decide on the current
symptom score.
Spirometry
FEV 1 values obtained through spirometry were
noted and the percentage change in FEV1 (PCFEV1)
was calculated at each visit, taking the FEV1 at the
beginning of the study as the baseline value . Al-
though this was an open trial, in order to eliminate
bias, the clinic secretaries recorded symptom scores
and the clinic physician conducted spirometry. Clinic
secretaries were strictly instructed not to discuss
with patients their mode of treatment. Also, patients
from both groups were assigned to different days for
clinic visits (even dates for the SIT group and odd
dates for the control group) so as to ensure that no
patients from one group would meet patients from
the other group during the course of this study．
Rescue Medication Records
Each patient was instructed to keep a careful record
of the number of doses of rescue salbutamol used.
Patients were asked to report back to the clinic if they
had any uncontrolled symptoms or clarifications. Pa-
tients not responding to salbutamol MDI were asked
to report to the clinic immediately and were pre-
scribed a short course of oral prednisolone, begin-
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Fig. 2　Percentage change and variation in symptom scores in the control (C) and specific immunother-
apy (SIT) groups over a period of 15 years
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Fig. 3　Corelation between mean % change in FEV1 and mean symptom scores 
in the specific immunotherapy (SIT) group
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Fig. 4　Corelation between mean % change in FEV1 and mean symptom scores 
in the control group
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ning with 30 mg per day and tapered off within 3
weeks.
Skin Prick Tests
SPT with D. farinae was repeated in all 85 patients be-
fore the beginning of the study (December 1986), on
discontinuation of SIT (January 1992) and on comple-
tion of the study (January 2002)．
Statistical Analysis
Analysis of the correlation coefficient was calculated
using Pearson’s test. The Mann Whitney test and Wil-
coxon Rank Sum test were used to compare the
symptom scores. PCFEV1 and SPT wheal sizes in the
two groups with p values < 0.05 were considered sta-
tistically significant. Area under the curve (AUC) was
used to compare the overall effect of SIT with the
control group over the entire duration of the 15 year
period. The SPSS statistical package was used to pre-
dict the maximum possible period of benefit obtained
with SIT．
RESULTS
Data obtained from this study showed that patients in
the control group suffered from their disease for 1 to
6 years (mean duration-2 years 7 months) whereas
those in the SIT group suffered for 1 to 7 years (mean
duration-3 years 5 months)．
Total serum IgE levels were in the range of 426 to
978 IUml. (mean-581 IUml.) in the control group
and 488 to 1007 IUml (mean - 602 IUml.) in the SIT
group．
Based on the International Consensus Report,7 all
69 cases were classified as“moderately severe
asthma．”Control group patients had FEV1.0 ranging
from 68% to 76% of predicted normal values (mean-
71%) while those in the SIT group had FEV1.0 rang-
ing from 66% to 70% (mean-70%)．
The baseline data in this study revealed that the
SIT and Control groups were well matched with re-
gard to age, sex, disease period, total serum IgE lev-
els and FEV1.0 (p< 0.05). This close match occurred
despite proper randomization and without any at-
tempt at stratification．
The results obtained from this study are shown in
Figures 1―4.
Both the PCFEV1 and the symptom scores were
evaluated for each time point over a period of 15
years for both SIT and control group. Data were ex-
pressed as means +- standard deviation (SD). Pa-
tients receiving SIT showed less variability in SD
whereas patients in the control group showed a large
variation over the 15-year period (Fig. 2).
Patients in the control group showed wide devia-
tions in mean symptom scores (range 2.60 to 6.21)
and in PCFEV1 (varying up to 7%) during the study
period. However, the SIT group showed a marked im-
provement through December 1987, a steady in-
crease until December 1993, followed by a gradual
decline until December 2001 (Fig. 2)．
Pearson correlations between mean PCFEV1 and
mean symptom scores (Figs. 3, 4) showed“a highly
significant correlation”in the SIT group ( r = 0.87, p
< 0.01) and“a significant correlation”in the control
group ( r = 0.58, p < 0.01)．
The Mann-Whitney Test was performed for symp-
tom scores. The null hypotheses of no difference be-
tween patients receiving SIT and control group was
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Table 1 AREA UNDER THE CURVE (AUC)
“p”values1987 to 20011992 to 20011987 to 1991GroupParameter
p < 0.05
569.10409.38159.72SIT
% change in FEV1.0 (PCFEV1)
278.11155.33122.78Control
p < 0.05
417.58277.73139.85SIT
Symptom Scores
247.21145.78101.43Control
rejected. There was a statistically significant differ-
ence between the two groups ( p < 0.01) with statisti-
cally significant higher symptom scores in the SIT
group．
Area under the curve (AUC) was estimated by
means of linear interpolation using the trapezoidal
rule (EquivTest, version 2.0, Solutions Ltd., Republic
of Ireland). AUC was calculated for both PCFEV1 and
symptom scores in both groups for the entire 15-year
period (1987 to 2001) and also separately for the pe-
riod during which SIT was administered ( 1987 to
1991) and the follow-up period (1992 to 2001)(Ta-
ble 1).For all 3 periods, the AUC analysis concluded
that the AUC is significantly higher for the SIT group
for both PCFEV1 and symptom scores ( p < 0.05)．
The two sample Wilcoxon Rank Sum Test and con-
fidence intervals ( CI ) for symptom scores and
PCFEV1 for March 1987 when compared with De-
cember 2001 for the SIT group showed a statistically
significant difference ( p < 0.05 ) and significantly
higher scores for December 2001．
The data obtained from this study was applied to
the SPSS version 11.0 statistical package in an at-
tempt to determine the maximum period of benefit
following cessation of SIT. The“curve fit method”，
predicted that symptom scores and PCFEV1 would
drop to zero in December 2014, which is after a dura-
tion of 28 years following initiation of the study (in
January 1987)．
The two-sample Wilcoxon Rank Sum Test was ap-
plied to the skin prick test data which revealed no sig-
nificant differences in wheal sizes when the 3 read-
ings (1986, 1992 and 2002) were compared to each
other in both the SIT and control groups．
Although side effects were not included in the
study plan, it is pertinent to note here that there were
no systemic reactions in the SIT group. There were
however, 20 episodes of small local reactions (<4 cm
in diameter) at the site of injection, none of which re-
quired therapeutic intervention．
The records maintained by patients revealed that
the control group inhaled a total of 61,400 puffs of sal-
butamol (approximately 307 MDI’s) during the first
year of this study as rescue medication. During the
same period the SIT group inhaled 8,600 puffs (or ap-
proximately 43 MDI’s). The difference therefore, be-
tween the two groups with regards to rescue medica-
tion, is stark. However, no reliable data could be ob-
tained for the rest of the study due to inaccurate re-
cording of MDI usage by patients in both groups．
None of the 31 patients in the SIT group needed
prednisolone during the 15-year study period. How-
ever, there were a total of 347 occasions when predni-
solone was administered to patients from the control
group ; thus on an average each control group pa-
tient required prednisolone 9 times during the study．
DISCUSSION
The end points used in this study, viz. PCFEV1 and
symptom scores are accepted as two of the most con-
venient methods of monitoring the clinical efficacy of
SIT. Bronchial hyper reactivity (BHR) was not con-
sidered as a parameter in this study since it has
yielded conflicting results in patients undergoing SIT.
Of the eight studies measuring BHR before and after
SIT, only one showed a decrease in BHR, but the re-
maining seven showed no change.9
In addition there have been conflicting results with
regard to changes in skin reactivity following SIT. In
13 out of 30 beneficial studies with SIT, four showed
no change and nine demonstrated decreased skin
test reactivity.10 Furthermore, the present study con-
firms that test reactivity is not a reliable end point for
studying the efficacy of SIT.
A number of studies have studied the efficacy of
SIT in asthma andor rhinitis over periods varying
from 1 to 6 years using house dust mite , tree and
grass pollen, fungi (Alternaria) and animal danders
(cat andor dog).11-21 Only one study observed the ef-
fects of SIT over a period of 14 years.22 However, that
study did not use any of the usual end points viz ,
symptom scores, PCFEV1, SPT wheal size or bron-
chial hyperresponsiveness. Indeed, this same study
did not discuss the details of statistical analysis.
The present study has shown a statistically signifi-
cant improvement in end points in the SIT group ,
which persisted for a decade after cessation of SIT
and using statistical projection would be expected to
last for approximately 13 years after completion of the
study (or for a total of 23 years following discontinu-
ation of SIT). This study concludes that contrary to all
current skepticism, SIT indeed has a long lasting
beneficial role in BA. In sum, SIT could therefore be
considered a truly disease modifying drug (DMD)．
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